New Zealand-based Mars Bioimaging has closed on $15 million in Series A funding.
Venture capital firm Pacific Channel led the round, which was raised in two tranches: $7.6 million in an initial close, followed by $7.4 million in new capital in 2026, the company said. New international investors include a Singapore-based med-sector company and an investor from Switzerland, Mars noted.
The company will use the new funding to accelerate the commercial adoption of its spectral photon-counting CT scanners, which deliver 3D color imaging with advanced material differentiation in key markets including the U.S., New Zealand, and select emerging markets such as India, Mars said.
